Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by ...
Federal health agencies, including the Centers for Medicare & Medicaid Services, have halted their communication efforts in ...
In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan ...
'The IRA's drug price controls are already hindering investment in critical drug research and development, undermining the innovation that has long made the U.S. a global leader in biopharmaceutical ...
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...
The General Enrollment Period provides an opportunity to make up for a past oversight – the failure to enroll in Part B.
Transparency in the program is more than just a mechanism for fair pricing—it is a driving force that diminishes the returns ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
As a primer from technology company MDInteractive explains it, “CMS implemented a multi-year transition from 2021 to 2024 for MSSP ACOs to move from reporting quality data through the CMS Web ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback